Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Worth $825 Million by 2017
DALLAS, May 27, 2013 /PRNewswire/ –
The “Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes
[SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)],
[Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017″ analyzes
and studies the major market drivers, restraints, and opportunities in Japan, China,
India, South Korea, Indonesia, Malaysia, Australia, New Zealand, and Rest of Asia.
- 146 Market Data Tables - 27 Figures - 313 Pages and an in-depth Table of Contents on "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market"
Early buyers will receive 10% customization on this report.
This report studies the Asia-Pacific nuclear medicine market over the forecast period
The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and
is poised to reach $824.9 million by 2017 at a CAGR of 10.5%.
Similar to the global nuclear medicine market, the Asia-Pacific region is also
minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron
facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to
capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m
market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for
Alzheimers disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm,
and ANSTO contributed more than 75% to the Asia-Pacific Nuclear
It is estimated that Tc-99m diagnostic procedures are expected to increase by more
than 30% in the developing markets of the Asia-Pacific region, including India, Australia,
and South Korea, between 2010 and 2030. The scheduled shutdown of the NRU reactor in
Canada in 2016 and OSIRIS in France in 2018 will not have any major impact in the near
future, since demand in this geographic region is compensated by local reactors such as
ANSTO. Radiopharmaceuticals are under clinical trials to extend applications. For
instance, preference for radiopharmaceuticals in neurological indications such as
Alzheimer’s, Parkinson’s and dementia are increasing besides conventional applications
such as cardiology and oncology. Furthermore, upcoming radioisotopes such as Ra-223
(Alpharadin) and Ga-68 possess huge potential for clinical applications.
Japan is the dominant Market for Diagnostic Radioisotopes with almost 40% share and
has around 1,600 gamma cameras, installed in about 1,120 institutions; PET diagnosis has
increased dramatically after 2002. The total number of PET institutes in Japan has
increased around 6-7 times in the last 10 years. Among Asia-Pacific countries, India,
South Korea, and Australia will be significant markets due to rising healthcare budgets
and increasing popularity of different radiopharmaceuticals in various clinical
indications. Processors such as ANSTO and other players from different geographies run
reactors that are involved in the irradiation of U-235 to make crude isotopes. They follow
various strategies to achieve sustainable growth, one of which is shifting to Low Enriched
Uranium (LEU) from High Enriched Uranium (HEU). These key players were mainly involved in
strategic agreements and contracts with other institutes and players, while generator
manufacturers followed several strategies to maintain a sustainable supply chain.
Asia-Pacific held the largest share in the Global Stable Isotopes Market in 2012. The
stable Isotopes Market was estimated at $56.1 million in 2012 and is poised to grow at
12.6% CAGR over the next five years. Growth of the Stable Isotope Market is driven by
proteomics and system biology research and applications such as Nuclear Magnetic Resonance
(NMR) and Mass Spectrometry (MS).
Buy a copy of this Report @
Browse Related Reports
- Nuclear Medicine/Radiopharmaceuticals Market [http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html ] - European Nuclear Medicine/Radiopharmaceuticals Market [http://www.marketsandmarkets.com/Market-Reports/european-nuclear-medicine-radiopharmaceuticals-market-1107.html ] - North American Nuclear Medicine/Radiopharmaceuticals Market [http://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html ]
MarketsandMarkets is a global market research and consulting company based in the U.S.
We publish strategically analyzed market research reports and serve as a business
intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and
custom research services. MarketsandMarkets covers thirteen industry verticals; including
advanced materials, automotives and transportation, banking and financial services,
biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power,
food and beverages, industrial automation, medical devices, pharmaceuticals,
semiconductors and electronics, aerospace & defense, agriculture industry.
We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.
Contact: Mr. Rohan North - Dominion Plaza 17304 Preston Road Suite 800, Dallas, TX 75252 Tel: +1-888-6006-441 Email: email@example.com Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets